StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$413.26+1.97 (+0.48%)

Close on Nov 17, 2026Market cap $46.99BP/E 73.9Yield –

BeOne Medicines total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

BeOne Medicines's total debt was $1.14B at Jun 30, 2026. For fiscal 2025 it was $1.03B, down 45.0% from the year before. The highest annual figure on record is $1.87B in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.03B-45.0%
FY2024Dec 31, 2024$1.87B+111.0%
FY2023Dec 31, 2023$885.98M+64.6%
FY2022Dec 31, 2022$538.12M-14.5%
FY2021Dec 31, 2021$629.68M-26.2%
FY2020Dec 31, 2020$853.67M+924.7%
FY2019Dec 31, 2019$83.31M+68.3%
FY2018Dec 31, 2018$49.51M+168.4%
FY2017Dec 31, 2017$18.44M+6.7%
FY2016Dec 31, 2016$17.28M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.14B+19.9%
Q1 FY2026Mar 31, 2026$1.09B+17.8%
Q4 FY2025Dec 31, 2025$1.03B-45.0%
Q3 FY2025Sep 30, 2025$813.30M-22.6%
Q2 FY2025Jun 30, 2025$954.49M-8.0%
Q1 FY2025Mar 31, 2025$923.63M-10.0%
Q4 FY2024Dec 31, 2024$1.87B+111.0%
Q3 FY2024Sep 30, 2024$1.05B+98.0%
Q2 FY2024Jun 30, 2024$1.04B+65.0%
Q1 FY2024Mar 31, 2024$1.03B+110.2%
Q4 FY2023Dec 31, 2023$885.98M+64.6%
Q3 FY2023Sep 30, 2023$531.05M-18.2%
Q2 FY2023Jun 30, 2023$628.48M+11.1%
Q1 FY2023Mar 31, 2023$488.11M-19.9%
Q4 FY2022Dec 31, 2022$538.12M-14.5%
Q3 FY2022Sep 30, 2022$649.33M+0.9%
Q2 FY2022Jun 30, 2022$565.94M-10.1%
Q1 FY2022Mar 31, 2022$608.99M+1.8%
Q4 FY2021Dec 31, 2021$629.68M-26.2%
Q3 FY2021Sep 30, 2021$643.28M+218.8%
Q2 FY2021Jun 30, 2021$629.66M+299.7%
Q1 FY2021Mar 31, 2021$598.06M+541.6%
Q4 FY2020Dec 31, 2020$853.67M+924.7%
Q3 FY2020Sep 30, 2020$201.77M+92.3%
Q2 FY2020Jun 30, 2020$157.55M+69.0%
Q1 FY2020Mar 31, 2020$93.21M+7.9%
Q4 FY2019Dec 31, 2019$83.31M+68.3%
Q3 FY2019Sep 30, 2019$104.93M+111.7%
Q2 FY2019Jun 30, 2019$93.23M+54.0%
Q1 FY2019Mar 31, 2019$86.42M+351.8%
Q4 FY2018Dec 31, 2018$49.51M+168.4%
Q3 FY2018Sep 30, 2018$49.56M+449.6%
Q2 FY2018Jun 30, 2018$60.53M+2350.8%
Q1 FY2018Mar 31, 2018$19.13M+10.7%
Q4 FY2017Dec 31, 2017$18.44M–
Q3 FY2017Sep 30, 2017$9.02M–
Q1 FY2017Mar 31, 2017$2.47M–
Q4 FY2016Dec 31, 2016$17.28M–

More BeOne Medicines figures

See a number that looks wrong?